Viridian Therapeutics, Inc. (0K1R.L)
USD 12.91
(0.7%)
USD 12.91
(0.7%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -81.77 Million USD | 45.6% |
| 2022 | -150.32 Million USD | -259.8% |
| 2021 | -41.77 Million USD | 8.06% |
| 2020 | -45.44 Million USD | -174.71% |
| 2019 | -16.54 Million USD | 25.85% |
| 2018 | -22.3 Million USD | 40.54% |
| 2017 | -37.51 Million USD | -1534.1% |
| 2016 | -2.29 Million USD | 76.4% |
| 2015 | -9.72 Million USD | -93.03% |
| 2014 | -5.03 Million USD | -1133.18% |
| 2013 | 487.71 Thousand USD | -97.83% |
| 2012 | 22.51 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -69.68 Million USD | 14.79% |
| 2024 Q2 | -86.7 Million USD | -24.43% |
| 2023 Q2 | -81.57 Million USD | 1.96% |
| 2023 Q3 | -90.77 Million USD | -11.28% |
| 2023 Q4 | -81.77 Million USD | 9.91% |
| 2023 FY | -81.77 Million USD | 45.6% |
| 2023 Q1 | -83.2 Million USD | 44.65% |
| 2022 Q1 | -30.27 Million USD | 27.53% |
| 2022 Q3 | -339.03 Million USD | -1197.58% |
| 2022 Q2 | -26.12 Million USD | 13.71% |
| 2022 Q4 | -150.32 Million USD | 55.66% |
| 2022 FY | -150.32 Million USD | -259.8% |
| 2021 Q1 | -46.13 Million USD | -1.52% |
| 2021 Q3 | -138.44 Million USD | -407.27% |
| 2021 Q4 | -41.77 Million USD | 69.82% |
| 2021 FY | -41.77 Million USD | 8.06% |
| 2021 Q2 | -27.29 Million USD | 40.84% |
| 2020 Q1 | -28.43 Million USD | -71.87% |
| 2020 Q2 | -21.38 Million USD | 24.77% |
| 2020 FY | -45.44 Million USD | -174.71% |
| 2020 Q4 | -45.44 Million USD | -118.06% |
| 2020 Q3 | -20.83 Million USD | 2.57% |
| 2019 Q2 | -13.85 Million USD | -77.57% |
| 2019 FY | -16.54 Million USD | 25.85% |
| 2019 Q4 | -16.54 Million USD | -5.86% |
| 2019 Q3 | -15.62 Million USD | -12.77% |
| 2019 Q1 | -7.8 Million USD | 65.02% |
| 2018 FY | -22.3 Million USD | 40.54% |
| 2018 Q1 | -68.08 Million USD | -81.46% |
| 2018 Q3 | -21.49 Million USD | 35.43% |
| 2018 Q4 | -22.3 Million USD | -3.78% |
| 2018 Q2 | -33.29 Million USD | 51.1% |
| 2017 Q1 | -49.95 Million USD | -2075.61% |
| 2017 FY | -37.51 Million USD | -1534.1% |
| 2017 Q4 | -37.51 Million USD | 4.85% |
| 2017 Q3 | -39.43 Million USD | 7.19% |
| 2017 Q2 | -42.48 Million USD | 14.95% |
| 2016 Q3 | -4.24 Million USD | 21.31% |
| 2016 Q4 | -2.29 Million USD | 45.93% |
| 2016 Q2 | -5.39 Million USD | 27.62% |
| 2016 Q1 | -7.45 Million USD | 23.36% |
| 2016 FY | -2.29 Million USD | 76.4% |
| 2015 Q4 | -9.72 Million USD | 11.73% |
| 2015 Q1 | -12.21 Million USD | -142.31% |
| 2015 FY | -9.72 Million USD | -93.03% |
| 2015 Q3 | -11.01 Million USD | -17.94% |
| 2015 Q2 | -9.34 Million USD | 23.48% |
| 2014 Q4 | -5.03 Million USD | 20.99% |
| 2014 Q1 | 903.41 Thousand USD | 85.23% |
| 2014 Q2 | -7.68 Million USD | -950.74% |
| 2014 Q3 | -6.37 Million USD | 17.02% |
| 2014 FY | -5.03 Million USD | -1133.18% |
| 2013 Q4 | 487.71 Thousand USD | 0.0% |
| 2013 FY | 487.71 Thousand USD | -97.83% |
| 2012 FY | 22.51 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | 150.561% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | 2010.724% |
| Codexis, Inc. | -43.27 Million USD | -88.993% |
| Organovo Holdings, Inc. | -1.5 Million USD | -5326.609% |